secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001655759-24-000140
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas/Pfizer report vepdegestrant+abemaciclib Phase 1b: 62.5% CBR, 26.7% ORR in post-CDK4/6 breast cancer
--------------------------------------------------------------------------------

- 62.5% clinical benefit rate (10/16) and 26.7% ORR (4/15) in ER+/HER2- advanced breast cancer patients all previously treated with CDK4/6 inhibitor.
- No significant drug-drug interaction between vepdegestrant (200mg QD) and abemaciclib (150mg BID); no grade 4/5 TEAEs.
- Recommended Phase 2 dose confirmed: vepdegestrant 200mg QD + abemaciclib 150mg BID; Phase 2 portion ongoing.
- Data cut-off Aug 30, 2024; presented Dec 12, 2024 at SABCS; 5 of 16 patients remain on treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000140/0001655759-24-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000140/arvn-20241210.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer